Experimental evidence indicates that Sfrp5 decreases accumulation of triglyceride and induction of hepatic steatosis through a pathway involving secreted lymphocyte antigen-6/urokinase-type plasminogen activator receptor-related peptide (Slurp-1) [44]. Here, SFRP5 is linked to fatty liver disease.